**ARTICLE IN PRESS** 

# Steroids xxx (2014) xxx-xxx

Contents lists available at ScienceDirect

# **Steroids**



journal homepage: www.elsevier.com/locate/steroids

# Trilobolide-porphyrin conjugates: On synthesis and biological effects evaluation

7 Q1 Pavla Tomanová<sup>a</sup>, Silvie Rimpelová<sup>b</sup>, Michal Jurášek<sup>a</sup>, Miloš Buděšínský<sup>c</sup>, Lucie Vejvodová<sup>d</sup>,
8 Tomáš Ruml<sup>b</sup>, Eva Kmoníčková<sup>d,\*</sup>, Pavel B. Drašar<sup>a,\*</sup>

۵ <sup>a</sup> Department of Chemistry of Natural Compounds, Institute of Chemical Technology in Prague, CZ-166 28 Prague, Czech Republic 10

<sup>b</sup> Department of Biochemistry and Microbiology, Institute of Chemical Technology in Prague, CZ-166 28 Prague, Czech Republic

11 <sup>c</sup> Institute of Organic Chemistry and Biochemistry, CZ-166 10 Prague, Czech Republic

12 <sup>d</sup> Institute of Pharmacology and Toxicology and Biomedical Centre, Faculty of Medicine in Pilsen, Charles University in Prague, CZ-301 66 Pilsen, Czech Republic

# ARTICLE INFO

30 18

5 6

3

- Article history: 19
- Received 15 June 2014 20
- Received in revised form 14 August 2014 21 Accepted 25 August 2014
- 22 Available online xxxx
- 23 Keywords:
- 24 Trilobolide
- 25 Porphyrin
- 26 Nitric oxide
- 27 Fluorescence microscopy 28

ABSTRACT

Trilobolide (Tb), a potent natural counterpart of thapsigargin, is a sesquiterpene lactone of guaianolide type isolated from horse caraway (Laser trilobum, L. Borkh). Tb exerts remarkable pharmacological properties based on irreversible inhibition of sarco/endoplasmic reticulum calcium ATPase (SERCA), thus being of increasing interest for cancer cure. Additionally, another pharmacological activity of Tb, as well as of thapsigargin, was reported in several studies. Tb as being an effective inductor of nitric oxide and cytokine production. These extraordinary biological properties move these molecules in further pre-clinical evaluation.

Because of ubiquitous character of SERCA expression, development of specifically targeted bioactive molecules is inevitable. Since it is well known that porphyrins are preferentially taken up by cancer cells, we have designed and synthesized novel Tb-porphyrin conjugates. Copper-catalyzed azide-alkyne cycloaddition was used to link Tb with porphyrin at once. Two model conjugates of Tb and porphyrin were synthesized and properly characterized. Employing naturally occurring fluorescence properties of porphyrins, we investigated the intracellular localization of the conjugates employing fluorescence microscopy in living cells. Intriguingly, the prepared conjugates localized both in mitochondria and lysosomes of HeLa and LNCaP cells. Furthermore, the cytotoxicity of Tb-porphyrin conjugates was assessed in a number of human cancer cell lines and rat peritoneal cells. Likewise in cancer cell lines, viability of rat peritoneal cells was not affected by the tested conjugates. Interestingly, we observed dose-dependent nitric oxide (iNOS) production induced by the tested conjugates. The effect was related to the type of a linker used and the overall size of the molecule. Another potent immunobiological effects are under evaluation.

In summary, the results presented here indicate notable immunobiological potential of the prepared Tb conjugates. Moreover, they could help to decipher the molecular mechanism of Tb for its possible biomedical applications.

© 2014 Published by Elsevier Inc.

53 54

64

65

66

67

68

69

70 71

72

73 74

75

76

30

31

32

33

34

35

36

37

38

39

40 41

42

43 44

45

46

47

48

49

50

51 52

### 1. Introduction 56

55

57

58 59

60 61

62

63

Porphyrins are a class of naturally occurring compounds which have become intensively studied in last decades due to their unique photochemical properties. The ability of porphyrins to passively target tumors in vivo enables their utilization in cancer therapy and diagnostics [1]. The passive tumor targeting by porphyrins is based on enhanced retention and permeability effect of solid tumors [2]. Photodynamic therapy (PDT) is a non-invasive therapeutic approach based on a use of light-sensitive molecules, photosensitizers. PDT is used worldwide for treatment of a number of diseases, including age-related macular degeneration, psoriasis and cancer [3–8]. Moreover, the photophysical properties of porphyrins allow visualization of their localization as well as of their conjugates both in vitro and in vivo. Conjugation of the macrocycle with counterpart of choice facilitates its transport via drug- or receptor-mediated endocytosis, affects delivery to a specific location within the cells and generally improves biological effects. Therefore, many drugs based on porphyrins are designed as prodrug systems to enhance their physico-chemical and pharmacokinetic properties [9]. Many groups have focused on conjugation of porphyrins with other biologically active compounds, such as

\* Corresponding authors.

http://dx.doi.org/10.1016/j.steroids.2014.08.024 0039-128X/© 2014 Published by Elsevier Inc.

Please cite this article in press as: Tomanová P et al. Trilobolide-porphyrin conjugates: On synthesis and biological effects evaluation. Steroids (2014), http://dx.doi.org/10.1016/j.steroids.2014.08.024

E-mail addresses: eva.kmonickova@lfp.cuni.cz (E. Kmoníčková), pavel.drasar@ vscht.cz (P.B. Drašar).

11 September 2014

137

161

2

P. Tomanová et al./Steroids xxx (2014) xxx-xxx

77 saccharides [10,13], peptides [12,14], steroids [15] and polymers 78 [16]. Conjugation is also responsible for specific accumulation in 79 cells [10], which determines biological effects of the conjugate. 80 Mitochondria [11], endoplasmic reticulum [10] and nucleus [12] 81 are believed to be the main organelles for the pharmacotherapeutic 82 intervention. Unfortunately, until now most of the conjugates 83 accumulate in endosomes and lysosomes, as it was described for 84 porphyrins conjugated to saccharides [10,13], peptides [14], dendrimers [15,16], and retinoids [17]. 85

86 In this study, we present synthesis of two porphyrin conjugates 87 containing a sesquiterpene lactone, trilobolide (Tb). Kmoníčková et al. [18] reported immunostimulatory properties of Tb, which is 88 able to induce interferon gamma (INF- $\gamma$ ) secretion and nitric oxide 89 90 (NO) release [18]. Another pharmacological feature of Tb is its potency to inhibit sarco/endoplasmic reticulum Ca<sup>2+</sup>-ATPase 91 92 (SERCA). The SERCA inhibition leads to accumulation of calcium ions in cytosol, and a sustained increase of Ca<sup>2+</sup> induces apoptotic 93 pathway and cell death. [19]. We imaged the transfer of the 94 prepared compounds in cells of various tumor origins. Biological 95 activities of the bioconjugates, such as induction of NO release in 96 97 rat macrophages have also been evaluated. Moreover, we assessed 98 cytotoxic potency of Tb-porphyrin conjugated in cancer cell lines 99 of various histogenic types.

## 100 2. Results and discussion

# 101 2.1. Chemistry

102 We chose copper-catalyzed azide-alkyne cycloaddition [20,21] (CuAAC) as the key reaction of the designed synthesis. Thus, both 103 parts of the conjugate, Tb and porphyrin, were modified to provide 104 105 intermediates suitable for click chemistry. The chemical transformation of Tb is displayed in Scheme 1 and all of the experimental 106 107 synthetic details are described in Supplementary Section 1. We 108 synthesized the carboxymethyloxime (CMO) derivative 1c in three 109 steps. Briefly, Tb was transformed to its demethylbutanoyl deriva-110 tive (1a) by mild solvolysis and successively the sole secondary 111 hydroxy group was oxidized using pyridinium chlorochromate 112 (PCC). Obtained 8-oxo-Tb derivative 1b was transformed to Tb-CMO 1c by the reaction with O-(carboxymethyl)hydroxyl-113 amine hemihydrochloride under pyridine catalysis. Finally, we 114 115 introduced terminal alkyne moiety by the reaction of 1c with 116 propargyl alcohol in presence of N-(3-dimethylaminopropyl)-N'-117 ethylcarbodiimide (EDC). Obtained propargylester 1d was used in 118 subsequent click reaction.

119 The synthesis of 5-(4-carboxyphenyl)-10,15,20-triphenylporfy-120 rin derivatives is displayed in Scheme 2. First we prepared the basic porphyrin according to a previously described method [22], 121 see Supplementary information 1.2.5 and Scheme S1. Thereafter, 122 we introduced azido PEG<sub>3</sub>-amine and propargyl moiety into the 123 porphyrin molecule using EDC chemistry (see Scheme 3). 124

Desired Tb-porphyrin conjugates were prepared using standard 125 click chemistry protocol with CuI and Tris[(1-benzyl-1H-1,2,3-126 triazolyl)-methyl]amine (TBTA) [23] as an accelerator of the 127 product formation. The analytical data including NMR, IR, HRMS, 128 and optical rotation characteristics are described in Supplementary 129 Section 1.2. Both conjugates showed absorbance maxima at 130 424 nm (Soret band) and emission maxima at 605 and 655 nm 131 (excitation wavelength of 429 nm; see Supplementary 1.3 and 132 Fig. S1), which are typical porphyrin spectral properties. Prior 133 to biological testing, all samples were re-purified by column chro-134 matography and their purity was checked by chromatographic 135 methods. 136

## 2.2. Intracellular localization of Tb-porphyrin conjugates

After successful synthesis of Tb-porphyrin conjugates, we stud-138 ied their intracellular localization in several human cancer cell 139 lines: HeLa, LNCaP, U-2 OS, MCF-7, and MiaPaCa-2. We performed 140 live-cell fluorescence microscopy of these red-emitting conjugates 141 (3 and 4) for time intervals ranging from 20 min up to 24 h. Detect-142 able fluorescent emission intensity of the tested derivatives 3 and 4 143 was observed only after 2 h of incubation with the model cell lines. 144 Thus, the kinetics of Tb-porphyrin conjugates was significantly 145 decreased when compared with the rapid intracellular uptake of 146 Tb-Bodipy occurring already after 20 min of incubation with 147 human cancer cells reported by Jurášek et al. [24]. In HeLa cells, 148 Tb-porphyrin **3** (5  $\mu$ M) localized in network-like patterned organ-149 elles, probably of mitochondrial origin, after 2 h of incubation. The 150 localization of **3** did not change over prolonged incubation periods 151 of 5 h (see Fig. 1), 16 h, and 24 h. Compound 4 (5 µM) was distrib-152 uted in vesicles of endosomal or lysosomal origin in HeLa cells after 153 2 h and the intracellular distribution was retained at least up to 154 24 h. Compound 4 occurred partially also in large fluorescent 155 aggregates probably caused by decreased water solubility. We 156 have observed similar behavior of both compounds in living pros-157 tatic cancer cells (LNCaP), data shown in Supplementary Section in 158 Fig. S2, and in human osteosarcoma cells (U-2 OS, see Fig. S3), the 159 only difference was more pronounced aggregation of compound 4. 160

## 2.3. NO production in primary macrophages

Within a group of sesquiterpene lactones, Tb possesses strong162activity in stimulating nitric oxide (NO) production by immune163



**Scheme 1.** Synthesis of functionalized Tb via carboxymethyloxime derivative. Reagents and conditions: (a) Et<sub>3</sub>N, MeOH, 17 h, rt, yield 69%; (b) PCC, CH<sub>2</sub>Cl<sub>2</sub>, rt, 2.5 h, yield 74%; (c) *O*-(carboxymethyl)hydroxylamine hemihydrochloride, pyridine, MeOH, rt, 70 min, yield 89%; (d) propargyl alcohol, EDC, HOBt, DMAP, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C  $\rightarrow$  rt, 12 h, yield 86%. Compound **1e** was available in our laboratory.

Please cite this article in press as: Tomanová P et al. Trilobolide-porphyrin conjugates: On synthesis and biological effects evaluation. Steroids (2014), http://dx.doi.org/10.1016/j.steroids.2014.08.024

# **ARTICLE IN PRESS**

### P. Tomanová et al./Steroids xxx (2014) xxx-xxx





Scheme 2. Synthesis of functionalized porphyrin. Reagents and conditions: EDC, DMAP, HOBt,  $CH_2Cl_2$ , 0 °C  $\rightarrow$  rt, 15 h, yield for 2a 55% and for 2b 84%.



Scheme 3. Synthesis of Tb-porphyrin conjugates via CuAAC reaction.

cells [25]. Based on this, we investigated nitric oxide release 164 induced by Tb-porphyrin conjugates (Fig. 2). We found different 165 166 effects of compounds tested in range of 0.01-100.0 µM. The highest NO release was induced by Tb-CMO derivative (1d). Also, the 167 168 potency of compound 1d with CMO link is closer to Tb itself than 169 to **1e** containing PEG<sub>4</sub> link. The ability of derivatives **1d** and **1e** to 170 induce NO production started at concentration of 1 µM and continued up to 40 µM concentration. It would be easy to simply 171 172 conclude that also Tb-porphyrin conjugates 3 and 4 possessed an 173 immunological activity even though weaker in comparison to Tb itself or Tb non-fluorescent derivatives. But together with these 174 findings, we mentioned that porphyrin alone in concentration 175 10-100 µM was able to release NO to supernatant in macrophages. 176 In fact, this result is probably caused by physico-chemical proper-177 ties of porphyrin. Standard analysis using Griess reagent was 178 179 applied to measure nitrite concentration. This spectrophotometric method is routinely used to assess NO production; absorbance is 180 recorded at 540 nm. Unfortunately, this wavelength coincided with 181 182 the absorption spectra of the tested porphyrins. Q-bands of Tb-porphyrin conjugates **3** and **4** in visible spectra overlap with 183 184 the absorbance wavelength (540 nm) for NO detection. Other than spectrophotometric methods used for NO detection in cell-free 185 186 samples are just under evaluation.

The effect of naturally occurring zinc protoporphyrin (ZnPP)was studied with respect to inducible HO-1 (heme oxygenase)

gene expression and activity [26,27]. ZnPP acts as competitive 189 inhibitor of HO-1. HO-1 is known to work opposite to iNOS and 190 both enzymes are studied in pro-inflammatory and anti-inflamma-191 tory conditions. It is interesting that no article has mentioned 192 possible interference of ZnPP with measurement of nitrite concen-193 tration using Griess reagent recorded at 540 nm, so far. Chow et al. 194 [26] and Li et al. [27] conclude that ZnPP directly inhibits inflam-195 matory iNOS expression (inducible nitric oxide synthase)/NO pro-196 duction in macrophages. However, we noticed that Tb-porphyrin 197 conjugates **3** and **4** induced slight up-regulation of NO production 198 stimulated by lipopolysaccharides (LPS, 1000 pg mL<sup>-1</sup>) in rat 199 macrophages. More detailed study is needed to thoroughly explain 200 biological activities of porphyrin conjugates and the role of 201 porphyrins in immune cells, as well as Tb itself in their estimated 202 pharmacological applications [28]. 203

# 2.4. Cytotoxicity assays

The Tb-porphyrin conjugates were tested for *in vitro* cytotoxicity against rat peritoneal cells and four human tumor cell lines: 206 LNCaP (prostate carcinoma), U-2 OS (osteosarcoma), MCF-7 (breast carcinoma), and MiaPaCa-2 (pancreatic carcinoma). The cytotoxic 208 activity was determined using WST-1 assay based on mitochondrial activity causing conversion of tetrazolium salt into a colored 210 product, formazan. The results are presented in Supplementary 211

204

Please cite this article in press as: Tomanová P et al. Trilobolide-porphyrin conjugates: On synthesis and biological effects evaluation. Steroids (2014), http://dx.doi.org/10.1016/j.steroids.2014.08.024

4

P. Tomanová et al./Steroids xxx (2014) xxx-xxx



**Fig. 1.** Intracellular localization of Tb–porphyrin conjugates **3** and **4** in human cervix cancer cells (HeLa). Fluorescence microscopy images of living cells incubated with 5  $\mu$ M concentration of compounds **3** and **4** for 5 h. Individual columns represent: bright field, fluorescence emission of Tb–porphyrin conjugates (Cy5 filter) and merge, respectively. The scale bar corresponds to 10  $\mu$ M.



**Fig. 2.** NO production in rat peritoneal cells induced by Tb and its derivatives. The cells were treated with Tb derivatives (**1d**, **1e**), porphyrins (**2a**, **2b**) and with Tb–porphyrins (**3, 4**) for 24 h. For evaluation of potential effects of Tb–porphyrin conjugates, Tb and lipopolysaccharide (LPS, 1000 pg mL<sup>-1</sup>) were used. The results represent the mean ± SEM of 2 independent experiments, *n* = 4.

Section in Fig. S4. Interestingly, we found that compounds 3 and 4 212 were not cytotoxic after 24 h and 48 h of incubation with the 213 214 model cell lines. The  $IC_{50}$  value was not reached in any of the tested 215 cell lines up to 50 µM concentration of the studied conjugates. Similar data for compounds **3** and **4** were found in primary rat 216 peritoneal cells measured after 24 h (data not shown). Thus, the 217 innate original cytotoxicity of pristine Tb reported by Kmoníčková 218 219 et al. [18] was not retained upon porphyrin conjugation. It might be caused by steric reasons and inefficient membrane penetration220in contrast to the original molecule in immune cells and cancer cell221lines as well.222

# 3. Conclusion

In conclusion, this is the first report on conjugation of a sesquiterpene lactone trilobolide with a red-emitting porphyrin moiety. 225

223

Please cite this article in press as: Tomanová P et al. Trilobolide-porphyrin conjugates: On synthesis and biological effects evaluation. Steroids (2014), http://dx.doi.org/10.1016/j.steroids.2014.08.024

5

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288 289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304 305

306

307

308

309

310

311

312 313

314

315

316

317

318

319

320 321

322 323

325

326

327

328

329

330

331

332

333

334

335

336

P. Tomanová et al./Steroids xxx (2014) xxx-xxx

226 Conjugates 3 and 4 were prepared in good yields and were 227 thoroughly characterized. On the basis of previously reported 228 immunostimulatory activities of a pristine Tb, we evaluated immu-229 nobiological potency of the prepared Tb-porphyrin conjugates in rat macrophages as a measure of NO production. The more pro-230 nounced NO production was induced by Tb-derivative 1d than by 231 232 Tb-porphyrin conjugates in comparison with Tb. Moreover, these compounds did not exhibit cytotoxic effect in vitro in a number 233 of model cell lines, such as primary macrophages, LNCaP, MCF-7, 234 U-2 OS, and MiaPaCa-2. The IC<sub>50</sub> value was not reached up to 50 235 236 µM concentration of the tested compounds. Utilizing the inherent fluorescence properties of porphyrins, we examined intracellular 237 localization of the Tb-porphyrin conjugates in living cells in real 238 time. Interestingly, the compounds 3 and 4 localized in mitochon-239 240 dria and lysosomes of the model cancer cell lines in 5 uM concen-241 tration already after 2 h. Further biological analysis is needed for differentiation between physico-chemical properties and possible 242 immunobiological effect (NO production) of porphyrin and its 243 conjugates in macrophages. 244

#### **Conflict of interest** 245

246 The authors declare no competing financial interest.

#### Acknowledgements 247

This work was supported by Czech Science Foundation (GAČR) 248 303/14/ 04329-S and MSMT No. 20/2014 and ED2.1.00/3.0076. 249 We thank Dr. Juraj Harmatha from IOCB AVCR (Prague) for gener-250

ous providing of trilobolide for this study. 251

### Appendix A. Supplementary data 252

253 Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.steroids.2014.08. 254 255 024.

#### References 256

271

- 257 [1] Swamy N, James DA, Mohr SC, Hanson RN, Ray R. An estradiol-porphyrin 258 conjugate selectively localizes into estrogen receptor-positive breast cancer 259 cells. Bioorg Med Chem 2002:10:3237-43.
- 260 Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and 261 the EPR effect in macromolecular therapeutics: a review. J Control Release 262 2000:65:271-84.
- 263 Jori G. Photodynamic therapy of microbial infections: state of the art and [3] 264 perspectives. J Environ Pathol Toxicol Oncol 2006;25:505-19. 265
- [4] Tandon YK, Yang MF, Baron ED. Role of photodynamic therapy in psoriasis: a 266 brief review. Photodermatol Photo 2008;24:222-30.
- 267 [5] O'Connor AE, Gallagher WM, Byrne AT. Porphyrin and nonporphyrin 268 photosensitizers in oncology: preclinical and clinical advances in 269 photodynamic therapy. Photochem Photobiol 2009;85:1053-74. 270
  - [6] Dolmans DE, Fukumura D, Jain RK. Photodynamic therapy for cancer. Nat Rev Cancer 2003;3:380-7.

- [7] Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, et al. Photodynamic therapy. J Natl Cancer Inst 1998;90:889-905.
- [8] Cruess AF, Zlateva G, Pleil AM, Wirostko B. Photodynamic therapy with verteporfin in age-related macular degeneration: a systematic review of efficacy, safety, treatment modifications and pharmacoeconomic properties. Acta Ophthalmol 2009:87:118-32.
- [9] Rautio J, Kumpulainen H, Heimbach T, Oliyai R, Oh D, Jarvinen T, et al. and clinical applications. Nat Rev Drug Discov Prodrugs: design 2008;7:255-70.
- [10] Di Stasio B, Frochot C, Dumas D. The 2-aminoglucosamide motif improves cellular uptake and photodynamic activity of tetraphenylporphyrin. Eur J Med Chem 2005;40:1111-22.
- [11] Sibrian-Vazquez M, Nesterova IV, Jensen TJ, Vicente MGH. Mitochondria targeting by guanidine- and biguanidine-porphyrin photosensitizers. Bioconjug Chem 2008;19:705-13.
- Sibrian-Vazquez M, Jensen TJ, Fronczek FR, Hammer RP, Vicente MGH. Synthesis and characterization of positively charged porphyrin-peptide conjugates. Bioconjug Chem 2005;16:852-63.
- [13] Csík G, Balog E, Voszka I, Tölgyesi F, Oulmi D, Maillard P, et al. Glycosylated derivatives of tetraphenyl porphyrin: photophysical characterization, selfmembrane binding. J Photochem Photobiol aggregation and B 1998;44:216-24.
- [14] Sibrian-Vazquez M, Jensen TJ, Vicente MGH. Influence of the number and distribution of NLS peptides on the photosensitizing activity of multimeric porphyrin-NLS. Org Biomol Chem 2010;8:1160-72.
- [15] Sadler S, Persons KS, Jones GB, Ray R. Internalization of a C17αalkynylestradiol-porphyrin conjugate into estrogen receptor positive MCF-7 breast cancer cells. Bioorg Med Chem Lett 2011;21:4638-41.
- [16] Shieh M-J, Peng C-L, Lou P-J, Chiu C-H, Tsai T-Y, Hsu C-Y, et al. Non-toxic phototriggered gene transfection by PAMAM-porphyrin conjugates. J Control Release 2008:129:200-6.
- [17] Sibrian-Vazquez M, Jensen TJ, Vicente MGH. Porphyrin-retinamides: synthesis and cellular studies. Bioconjug Chem 2007;18:1185–93. [18] Kmoníčková E, Harmatha J, Vokáč K, Kostecká P, Farghali H, Zídek Z.
- Sesquiterpene lactone trilobolide activates production of interferon-gamma and nitric oxide. Fitoterapia 2010;81:1213-9.
- [19] Winther A-ML, Liu H, Sonntag Y, Olesen C, Le MM, Soehoel H, et al. Critical roles of hydrophobicity and orientation of side chains for inactivation of sarcoplasmic reticulum Ca<sup>2+</sup>-ATPase with thapsigargin and thapsigargin analogs. | Biol Chem 2010;285:28883-92.
- [20] Huisgen R. Kinetics and mechanism of 1,3-dipolar cycloadditions. Angew Chem Int Ed 1963;75:633-45.
- [21] Sharpless KB. Click chemistry: discovery of new medicines. Abstr Pap Am Chem Soc 2011:241.
- [22] Borocci S, Marotti F, Mancini G, Monti D, Pastorini A. Selectivity in the oxidation of limonene by amphiphilized metalloporphyrins in micellar media. Langmuir 2001;17:7198-203.
- [23] Hein JE, Tripp JC, Krasnova LB, Sharpless KB, Fokin VV. Copper(I)-catalyzed cycloaddition of organic azides and 1-iodoalkynes. Angew Chem Int Ed 2009:48:8018-21.
- [24] Jurášek M., Rimpelová S., Kmoníčková E., Drašar P., Ruml T. Tailor-made fluorescent trilobolide to study its biological relevance. Article under revision. Q2 324 2014
- [25] Harmatha J, Buděšínský M, Vokáč K, Kostecká P, Kmoníčková E, Zídek Z. Trilobolide and related sesquiterpene lactones from Laser trilobum possessing immunobiological properties. Fitoterapia 2013;89:157-66.
- [26] Chow I-M. Lin H-Y. Shen S-C. Wu M-S. Lin C-W. Chiu W-T. et al. Zinc protoporphyrin inhibition of lipopolysaccharide-, lipoteichoic acid-, and peptidoglycan- induced nitric oxide production through stimulating iNOS protein ubiquitination. Toxicol Appl Pharmacol 2009;237:357-65.
- [27] Li B, Lee D-S, Choi H-G, Kim K-S, Kang D-G, Lee H-S, et al. Sauchinone suppresses pro-inflammatory mediators by inducing heme oxygenase-1 in RAW264.7 macrophages. Biol Pharm Bull 2011;34:1566-71.
- [28] Kmoníčková E., Zídek Z., Harmatha J., Buděšínský M., Vokáč M. Immunostimulatory activity of trilobolide and method of separation thereof. WO/2009/010021 (AI)-2009-01-22.

337 338